Alprostadil: an effective antiplatelet agent for calves.
Alprostadil: an effective antiplatelet agent for calves.
复制标题
Alprostadil：一种有效的犊牛抗血小板药物。
DOI：
10.1111/j.1525-1594.1993.tb00406.x
复制
发表时间：
1993
影响因子：
2.4
通讯作者：
Olsen,DB
中科院分区：
文献类型：
--
作者：
Jaarsma,RL;Mohammad,SF;Burns,GL;Olsen,DB
阿司匹林和其他非甾体类抗炎药物抑制人血小板，但它们作为抗血小板剂对牛血小板的作用尚不确定。由于小牛被用于心血管植入研究，因此需要一种有效的抗血小板药物。在筛选了许多潜在的小牛抗血小板药物后，前列地尔（前列腺素E1）似乎是最有希望的。8头小牛给予前列地尔（静脉连续滴注）。给药浓度逐渐增加，直至获得50%的血小板聚集抑制。密切监测血小板功能、血压、体温和血液学参数。为了进行体外评价，将前列地尔添加到人或牛的血液中，并测量血小板聚集和环磷酸腺苷水平。前列地尔对牛和人的血小板均有抑制作用，但牛的血小板对该药的反应相对较好。体内输注速率约为0.20 pg/kg/min时，前列地尔对血小板聚集的抑制作用为50%，血压略有下降（7±6 mm Hg），但无不良反应。体内血小板抑制在停药后24小时内完全逆转。这种较短的半衰期和缺乏明显的不良反应使前列地尔成为一种有吸引力的抗血小板药物，用于心血管植入的小牛。
Aspirin and other nonsteroidal, antiinflammatory drugs inhibit human platelets, but their effect as an antiplatelet agent on bovine platelets is not certain. Since calves are used for cardiovascular implant research, need exists for an effective antiplatelet agent for this animal model. After screening a number of potential antiplatelet drugs for calves, Alprostadil (prostaglandin E1) appeared to be the most promising. Alprostadil was administered (intravenous continuous drip) to 8 calves. The concentration of the drug administered was gradually increased until 50% inhibition of platelet aggregation was obtained. Platelet function, blood pressure, body temperature, and hematologic parameters were closely monitored. For in vitro evaluation, Alprostadil was added to human or bovine blood, and the platelet aggregation and cyclic adenosine monophosphate levels were measured. Alprostadil inhibited both bovine and human platelets, although bovine platelets were relatively more responsive to this drug. At an infusion rate of approximately 0.20 pg/kg/min in vivo, Alprostadil showed 50% inhibition of platelet aggregation with slightly decreased blood pressure (7 ± 6 mm Hg) but no adverse effects. Complete reversal of in vivo platelet inhibition was noted within 24 h after cessation of drug administration. This short half‐life and the lack of significant adverse effects make Alprostadil an attractive antiplatelet agent for calves with cardiovascular implants.